The purpose of this research study is to look at the efficacy (the effect on tumor) and the
safety (the effect on body) of the study drugs when given as a combination in patients with
metastatic recurrent epidermal growth factor receptor 2 (HER2) negative inflammatory breast
cancer. This is a phase II study of 2 drugs used in combination: nivolumab and ipilimumab.
The combination of these drugs is already approved by the Food and Drug Administration (FDA)
to treat advanced melanoma (a type of skin cancer). Nivolumab and ipilimumab are not approved
by the FDA for patients with metastatic recurrent HER2 negative inflammatory breast cancer,
hence the treatment is considered experimental or investigational.